TRVI - CIK 0001563880
The table below shows Trevi Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$16.69M | -$13.48M | -$10.47M | -$8.20M | -$7.09M | -$7.58M |
| Capital expenditure | $102.00K | - | - | $57.00K | - | - |
| Investing cash flow | $16.96M | -$9.95M | -$8.09M | $8.96M | - | - |
| Dividends paid | - | - | - | - | - |
Trevi Therapeutics, Inc. reported operating cash flow of -$42.09M for fiscal year 2025. That is down 10.0% from -$38.26M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$18.29M (FY 2018) to -$42.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $222.00K | $8.71M | -$28.00K | -$1.70M | -$625.00K | $4.15M |